Hepion Total Operating Expenses vs Net Interest Income Analysis
HEPA Stock | USD 1.52 0.16 11.76% |
Hepion Pharmaceuticals financial indicator trend analysis is much more than just examining Hepion Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hepion Pharmaceuticals is a good investment. Please check the relationship between Hepion Pharmaceuticals Total Operating Expenses and its Net Interest Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.
Total Operating Expenses vs Net Interest Income
Total Operating Expenses vs Net Interest Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hepion Pharmaceuticals Total Operating Expenses account and Net Interest Income. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Hepion Pharmaceuticals' Total Operating Expenses and Net Interest Income is 0.81. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Net Interest Income in the same time period over historical financial statements of Hepion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Hepion Pharmaceuticals' Total Operating Expenses and Net Interest Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Hepion Pharmaceuticals are associated (or correlated) with its Net Interest Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Interest Income has no effect on the direction of Total Operating Expenses i.e., Hepion Pharmaceuticals' Total Operating Expenses and Net Interest Income go up and down completely randomly.
Correlation Coefficient | 0.81 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most indicators from Hepion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hepion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.At present, Hepion Pharmaceuticals' Enterprise Value Over EBITDA is projected to drop slightly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to 9,137.
Hepion Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Hepion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hepion Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 20.6M | 48.6M | 103.6M | 60.2M | 18.1M | 27.5M | |
Other Current Liab | 851.2K | 659.6K | 3.0M | 366.2K | 386K | 366.7K | |
Total Current Liabilities | 1.6M | 4.7M | 8.2M | 7.9M | 5.3M | 3.8M | |
Total Stockholder Equity | 15.6M | 40.5M | 93.0M | 49.9M | 7.3M | 6.9M | |
Net Debt | (13.1M) | (40.0M) | (91.0M) | (51.1M) | (14.6M) | (15.3M) | |
Retained Earnings | (83.8M) | (104.1M) | (133.5M) | (175.7M) | (224.6M) | (213.4M) | |
Accounts Payable | 491.6K | 3.7M | 2.4M | 2.7M | 2.3M | 2.0M | |
Cash | 13.9M | 40.7M | 91.3M | 51.2M | 14.8M | 22.3M | |
Cash And Short Term Investments | 13.9M | 40.7M | 91.3M | 51.2M | 14.8M | 24.2M | |
Common Stock Total Equity | 1.7K | 375.0 | 3.2K | 7.6K | 8.8K | 9.2K | |
Common Stock Shares Outstanding | 102.2K | 483.9K | 3.5M | 3.8M | 4.0M | 4.2M | |
Liabilities And Stockholders Equity | 20.6M | 48.6M | 103.6M | 60.2M | 18.1M | 27.5M | |
Non Current Liabilities Total | 3.4M | 3.5M | 2.4M | 2.5M | 5.5M | 4.0M | |
Other Stockholder Equity | 97.7M | 142.9M | 224.8M | 223.9M | 230.3M | 241.8M | |
Total Liab | 5.0M | 8.1M | 10.6M | 10.4M | 10.8M | 7.7M | |
Total Current Assets | 14.4M | 42.6M | 97.5M | 56.5M | 17.5M | 24.0M | |
Common Stock | 25.0 | 375.0 | 3.2K | 7.6K | 482.0 | 457.9 | |
Non Currrent Assets Other | 306.9K | 285.1K | 583.3K | 426.2K | 301.7K | 222.4K | |
Property Plant And Equipment Gross | 855.1K | 108.4K | 696.7K | 439.2K | 621.8K | 652.9K | |
Property Plant And Equipment Net | 855.1K | 664.9K | 456.5K | 132.2K | 242.4K | 289.1K | |
Non Current Assets Total | 6.2M | 6.0M | 6.1M | 3.7M | 606.6K | 576.2K | |
Other Assets | 3.3M | 4.0M | 583.3K | 426.2K | 490.1K | 465.6K | |
Capital Surpluse | 76.7M | 97.7M | 142.9M | 223.9M | 257.5M | 270.4M | |
Other Current Assets | 465.7K | 1.9M | 6.1M | 5.3M | 2.7M | 2.0M | |
Property Plant Equipment | 855.1K | 664.9K | 456.5K | 81.6K | 93.9K | 89.2K | |
Short Long Term Debt Total | 807.4K | 752.2K | 317.0K | 53.6K | 209.0K | 360.0K | |
Other Liab | 2.5M | 3.0M | 2.3M | 2.5M | 2.3M | 3.2M | |
Net Tangible Assets | 12.6M | 36.9M | 86.2M | 45.0M | 51.7M | 54.3M | |
Non Current Liabilities Other | 2.4M | 2.6M | 1.9M | 2.1M | 1.6M | 2.0M | |
Net Invested Capital | 14.5M | 39.0M | 91.3M | 48.2M | 5.6M | 5.3M | |
Net Working Capital | 13.1M | 38.0M | 89.2M | 48.6M | 12.2M | 11.6M | |
Short Term Debt | 266.7K | 279.8K | 266.7K | 53.6K | 115.9K | 110.1K | |
Capital Stock | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.32) | Return On Assets (0.72) | Return On Equity (1.71) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.